Summit Therapeutics (NASDAQ: SMMT) - RICH TV LIVE PODCAST

Summit Therapeutics (NASDAQ: SMMT) - RICH TV LIVE PODCAST - December 8, 2022 - #summittherapeutics #pennystocks #richtvlive #business #news #finance #education

Summit Therapeutics, Inc. is honored to announce a definitive agreement of its partnership with Akeso Inc. (HKEX Code: 9926.HK, “Akeso”), to in-license its breakthrough bispecific antibody, ivonescimab. Akeso is a pioneer and source originator in developing innovative antibodies. The agreement supports Summit’s mission of developing and commercializing groundbreaking oncology pipeline products aimed at improving the quality of life of patients with serious unmet medical needs. For Akeso, the deal represents an opportunity to introduce its highly innovative antibodies to markets, including the United States, Canada, Europe, and Japan – an important step towards Akeso’s strategic intention of becoming a global biopharma organization.​

Subscribe - https://www.youtube.com/c/RICHTVLIVE

Social Media Links - https://linktr.ee/richtvlive

Visit - http://richtv.io/ a community for stocks, cryptocurrency, nfts, metaverse, news, and trending topics. #richtvlive #richtv #richpicksdaily #stocks #business #news #finance #education #entertainment #money #defi #nft #metaverse #trading #stockmarket #podcast

Ledger - Home of the first and only certified Hardware wallets
https://bit.ly/richtv-Ledger

Popular Uploads - https://goo.gl/tbvXGg
Most Recent Upload - https://goo.gl/unKXBy
YouTube Channel Page - https://goo.gl/yUdG7w
Subscribe - http://www.youtube.com/c/RICHTVLIVE
Rich TV Live Playlist - https://goo.gl/e116JF
RICH TV LIVE TOP 10 STOCKS Playlist - https://www.youtube.com/playlist?list...

Disclaimer

RICH TV LIVE INC. company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RICH TV LIVE reports company profiles or other investor relations materials and presentations are subject to change. RICH TV LIVE and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.

Investing is inherently risky. RICH TV LIVE is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.

We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov/Canadian CSA https://www.securities-administrators....
​Ivonescimab, known as AK112 in China and Australia, and also as SMT112 in the United States, Canada, Europe, and Japan, is a novel, potential first-in-class bispecific antibody combining the power of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-VEGF into a single molecule. Ivonescimab is believed to be the PD-1 / VEGF bispecific antibody that is most advanced in the clinic: there are no known PD-1-based bispecific antibodies approved by the US Food and Drug Administration (“FDA”) or the European Medicines Agency (“EMA”). ​

​Akeso has already demonstrated success by commercializing the only PD-1 bispecific. It’s product 开坦尼 (pronounced “Kaitanni”) (cadonilimab), a PD-1 / CTLA-4 bispecific, was approved by the Chinese National Medical Products Administration (“NMPA”) earlier this year for the treatment of relapsed or metastatic cervical cancer patients who progressed on or after platinum-based chemotherapy.